A Study of LY3323795 in Healthy Participants
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 20 - Any |
| Updated: | 4/17/2018 |
| Start Date: | December 12, 2016 |
| End Date: | July 21, 2017 |
Single-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3323795 in Healthy Subjects
The main purpose of this study is to investigate the safety of LY3323795 and the effects it
has on the body. The study drug or placebo (sugar pill) will be given by mouth to healthy
participants. The study has three parts. Each participant may only enroll in one part. The
study will last 14 to 43 days, depending on the part. Screening must be completed prior to
study start.
has on the body. The study drug or placebo (sugar pill) will be given by mouth to healthy
participants. The study has three parts. Each participant may only enroll in one part. The
study will last 14 to 43 days, depending on the part. Screening must be completed prior to
study start.
Inclusion Criteria:
- Healthy males or females of non-childbearing potential at time of screening
- Have a body mass index (BMI) between 18.0 kilograms per square meter (kg/m²) and 32.0
kg/m², inclusive
Exclusion Criteria:
- Have participated, within the last 30 days, in a clinical trial involving an
investigational product.
- Have a QT corrected for heart rate (QTc) (using Bazett's formula) interval value of
greater than 450 millisecond (msec) (males) or greater than 470 msec (females)
We found this trial at
1
site
Glendale, California 91206
Principal Investigator: Hakop Gevorkyan, MD
Phone: 818-254-1624
Click here to add this to my saved trials
